Germany advises on Covid-19 vaccine CHOICE for under-30s — RT World News

Germany’s advisory panel for vaccines has recommended that anyone under the age of 30 receive Pfizer BioNTech’s Covid jab. This is due to increased heart inflammation after Moderna shots.

Announcing its advice in a statement released on Wednesday, the body – known by its acronym STIKO – said that current reporting indicates that heart muscle and pericardial inflammation in boys and girls, as well as in young men and women under 30, was more frequently seen following vaccination with Moderna’s Spikevax, in comparison to Pfizer’s Comirnaty.

STIKO made the recommendation based on safety data and international findings from the Paul Ehrlich Institute in Germany. As per the notice, the advice applies to both first and second doses, as well as to boosters – even if a different inoculant was used previously.

It is important that all pregnant women be vaccinated with Comirnaty regardless of their age.

Also available at
France offers new information on Moderna Covid jab

STIKO’s recommendation is just a few days after France’s Haute Autorite de Sante, a public health agency, advised against immunizing children under 30 with Spikevax. It was based on an increased risk of severe heart disease. Recent data from HAS shows that myocarditis risk is approximately five times lower with Pfizer’s jab.

Moderna vaccine was banned in the Nordic states last month. Iceland is the largest, suspending vaccination for all its citizens.

Stockholm decided to stop using it for Swedes born between 1991 and 2002. Finland however announced that Moderna would not be used for younger males. The Moderna restrictions were based on the findings of a Nordic study, which showed that those aged 25-34 years old are more susceptible to myocarditis. Norway also recommends that young men get the Pfizer jab. also available
Finland stops Moderna vaccines for young men because of concerns about heart inflammation

This story is worth sharing with your friends!



Related Articles

Back to top button